{
  "id": "compulsory-license",
  "title": "Compulsory License",
  "lang": "en",
  "source_lang": "en",
  "summary": "A compulsory license authorizes specified uses of protected intellectual property without the right holder’s consent, subject to legal conditions and usually remuneration.",
  "category": "society",
  "subcategory": "law",
  "type": "concept",
  "aliases": [
    "Compulsory licence",
    "non-voluntary license",
    "non-voluntary licence"
  ],
  "generated_at": "2026-11-03",
  "model": "pro/gpt-6.1-sol",
  "url": "https://aiwiki.page/en/compulsory-license/",
  "translations": {
    "zh-Hans": {
      "url": "https://aiwiki.page/zh/compulsory-license/",
      "json": "https://aiwiki.page/zh/compulsory-license.json"
    }
  },
  "sections": [
    {
      "heading": "",
      "text": "A compulsory license is a legal authorization to use protected intellectual property without the consent of its owner. It does not ordinarily transfer ownership or invalidate the protected right. Instead, it replaces the owner’s power to refuse a particular use with an entitlement to remuneration and compliance with legally prescribed conditions. Compulsory licensing is especially important in patent and copyright law, although its purposes and operation differ considerably between these fields.\n\nThe mechanism addresses circumstances in which exclusive control conflicts with other legally recognized interests, including access to medicines, correction of anticompetitive conduct, exploitation of dependent inventions, and efficient distribution of cultural works. Some licenses require an individual administrative or judicial decision; others arise directly under legislation once a user satisfies specified requirements. Patent licenses generally concern particular inventions and uses, whereas copyright statutory licenses may establish continuing systems for entire categories of activity.\n\nNational legislation determines who may request or exercise a license, which grounds justify it, and how remuneration is calculated. International agreements constrain that discretion without imposing a single worldwide model. The resulting institution sits at the intersection of private rights, public regulation, industrial policy, and international trade."
    },
    {
      "heading": "Legal character and boundaries",
      "text": "An intellectual property right ordinarily gives its owner authority to exclude others from specified acts. A patent may cover making, using, selling, or importing a claimed invention; copyright controls defined acts such as reproduction, distribution, and certain performances or communications. A compulsory license removes the need for consent for particular acts within a defined legal framework. Conduct outside that framework can remain intellectual property infringement.\n\nUnlike an ordinary agreement under intellectual property licensing, a compulsory license derives its essential authority from law rather than the owner’s voluntary assent. A licensing authority may determine the product, territory, duration, permitted quantities, eligible licensees, and payment obligations. The owner usually retains the right and can continue exploiting it or granting voluntary licenses. Compulsory patent licenses are commonly non-exclusive, allowing the original proprietor and potentially several authorized competitors to operate simultaneously.\n\nTerminology varies between legal systems. “Compulsory license” sometimes means an authorization granted after an individual application, while “statutory license” describes permission available automatically to users who satisfy legislative conditions. Copyright discussions often preserve this distinction; broader international discussions frequently group both arrangements as non-voluntary licensing. Government use of patents may belong to a related but separately regulated category, particularly when public procurement rather than ordinary commercial competition is involved.\n\nSeveral neighboring mechanisms have different legal effects. Expiration places formerly protected subject matter in the public domain, while invalidation removes a right because legal requirements were not met. An exception such as fair use permits certain conduct without obtaining a license and ordinarily without a royalty. Exhaustion limits control over particular goods after an authorized sale; it does not normally authorize manufacturing new copies. A compulsory license, by contrast, generally leaves the underlying exclusive right intact and authorizes conduct that would otherwise require permission.\n\nThe authorization is also narrower than an unrestricted entitlement to operate a business. A license under one patent does not necessarily clear other patents covering a product or manufacturing process. It does not automatically confer rights to a trademark, confidential manufacturing instructions, regulatory dossiers, or protected software. Pharmaceutical manufacturers must still satisfy applicable safety and quality requirements. These distinctions are central to understanding why legal permission to use an invention does not necessarily produce immediate commercial supply."
    },
    {
      "heading": "Historical development and international foundations",
      "text": "Compulsory patent licensing developed partly from concerns that patents might be acquired but not put into practical use within the granting country. Nineteenth-century industrial policy frequently connected patent protection with domestic production and the dissemination of technical knowledge. Legal systems used working requirements, forfeiture, and later compulsory licenses to address non-use. Licensing offered a less destructive response than cancelling the patent altogether: the proprietor retained a protected asset, but another enterprise could receive permission to exploit it.\n\nThe Paris Convention for the Protection of Industrial Property, adopted in 1883 and subsequently revised, became a central international framework. Article 5A recognizes that member countries may provide compulsory licenses to prevent abuses resulting from patent rights, including failure to work an invention. For licenses based on failure to work or insufficient working, it establishes waiting periods: an application generally cannot be made before four years from filing or three years from grant, whichever expires later. A license must be refused if the proprietor justifies the inaction through legitimate reasons.\n\nThose Paris Convention rules do not establish a universal waiting period for every compulsory license. Their particular subject is licensing for failure to work or insufficient working. The convention also restricts forfeiture: proceedings to revoke a patent on the relevant grounds cannot begin before two years have elapsed from the grant of the first compulsory license. This structure treats licensing as an intermediate remedy before the more severe loss of the patent.\n\nA broader framework emerged through the Agreement on Trade-Related Aspects of Intellectual Property Rights, or TRIPS, which entered into force in 1995 with the establishment of the World Trade Organization. Article 31 regulates “other use” of patented subject matter without the right holder’s authorization, including government-authorized use. It sets conditions involving individual consideration, prior negotiations in ordinary circumstances, limited scope and duration, non-exclusivity, remuneration, and review. It does not provide an exhaustive list of permissible public-interest grounds.\n\nThe 2001 Doha Declaration on the TRIPS Agreement and Public Health clarified that TRIPS can and should be interpreted and implemented to support members’ right to protect public health. It affirmed each member’s freedom to determine the grounds for compulsory licenses and what constitutes a national emergency or other circumstance of extreme urgency. The declaration was especially significant for HIV/AIDS, tuberculosis, malaria, and other epidemics, but its affirmation of public-health flexibility was not confined to those diseases.\n\nCopyright developed through a different treaty structure. The Berne Convention permits particular non-voluntary licensing arrangements, including specified conditions for broadcasting and sound recording, while its Appendix provides special mechanisms for certain translation and reproduction licenses in developing countries. These are subject-specific permissions rather than a general equivalent of the patent framework in TRIPS Article 31."
    },
    {
      "heading": "Grounds for patent licensing and government use",
      "text": "National patent laws identify the circumstances in which an authority may authorize unconsented use. Common grounds include unmet public needs, failure to exploit an invention, inadequate supply, dependent patents, anticompetitive conduct, and government requirements. The existence of a ground does not itself create a license: the applicant must usually establish the statutory facts and obtain an authorization. Conversely, a country need not characterize every compulsory license as a response to an emergency.\n\nPublic-interest provisions often focus on whether a patented product is available in sufficient quantities or on terms compatible with public needs. Their wording matters. A statute referring to reasonable public requirements may require different evidence from one directed specifically at excessive prices, inadequate domestic working, or national security. The international framework leaves substantial discretion, but the decision must still comply with domestic legislation and relevant treaty obligations.\n\nA dependent invention illustrates a different problem. A later patented invention may improve an earlier invention but remain impossible to practice without infringing the earlier patent. TRIPS Article 31(l) permits compulsory licensing in this situation under additional conditions. The later invention must involve an important technical advance of considerable economic significance relative to the first. The earlier patent owner must be entitled to a cross-license on reasonable terms to use the later invention, and the license to the earlier patent generally cannot be assigned separately from the later patent.\n\nGovernment use is often designed to secure supplies or services for public purposes. Under TRIPS, public non-commercial use can dispense with the ordinary requirement to seek voluntary authorization first, although notification requirements remain. Domestic law may permit a ministry, contractor, or other designated entity to undertake the authorized acts. Whether a particular procurement arrangement qualifies depends on its legal structure and the governing legislation, not simply on the fact that a government buys the resulting product.\n\nIn the United States, 28 U.S.C. §1498 provides a distinctive mechanism for patented inventions used or manufactured by or for the federal government without authorization. Subject to the statutory requirements, the owner’s remedy is an action for reasonable and entire compensation against the United States in the Court of Federal Claims. This is commonly analyzed alongside compulsory licensing, although it operates as a government-use compensation regime rather than an ordinary application for a commercial license.\n\nThe absence of an automatic injunction in an infringement case is another related but distinct development. Following eBay Inc. v. MercExchange, L.L.C. in 2006, United States patent injunctions depend on traditional equitable factors rather than an automatic rule. A court’s refusal to prohibit continued use, sometimes accompanied by an ongoing royalty, can produce results resembling a non-voluntary license. Its doctrinal basis, however, differs from statutory compulsory licensing."
    },
    {
      "heading": "Authorization, remuneration, and procedural safeguards",
      "text": "Under TRIPS Article 31, authorization must ordinarily be considered on its individual merits. Before seeking a license, a proposed user must generally have attempted to obtain permission on reasonable commercial terms and conditions and failed within a reasonable period. This requirement distinguishes compulsory licensing from an immediate entitlement to substitute a publicly determined royalty for the owner’s requested price. Domestic procedures determine what evidence demonstrates a genuine attempt and how long negotiations must continue.\n\nThe negotiation requirement may be waived in a national emergency, other circumstances of extreme urgency, or public non-commercial use. Different notification rules accompany these exceptions. In an emergency or urgent situation, the right holder must nevertheless be notified as soon as reasonably practicable. For public non-commercial use, prompt information is required in specified circumstances where the government or contractor knows, or has demonstrable grounds to know, that a valid patent is being used. Waiver of prior negotiation does not generally eliminate remuneration.\n\nA license must have a scope and duration limited to its authorized purpose. Under Article 31, it must be non-exclusive and generally non-assignable except with the relevant enterprise or goodwill. Authorization is liable to termination when the circumstances that justified it cease and are unlikely to recur, subject to adequate protection of the legitimate interests of authorized users. Authorities must therefore reconcile temporary intervention with practical requirements such as investment recovery, manufacturing continuity, and existing supply commitments.\n\nThe right holder must receive “adequate remuneration in the circumstances of each case,” taking into account the authorization’s economic value. TRIPS establishes no universal royalty percentage. A national authority may examine comparable voluntary licenses, the patent’s technical contribution, the relevant product market, public expenditure, and the authorized volume of sales. Where several patents cover the same product, simply adding independently calculated royalties can overstate the value of the combined authorization.\n\nPayment design is as important as the headline rate. A percentage of net sales can yield a different result from a percentage of a reference price, and both differ from a fixed payment per unit. Reporting requirements, permitted deductions, exchange-rate rules, audit rights, and payment timing influence actual compensation. These administrative provisions also allow authorities to verify that licensees remain within authorized quantities and uses.\n\nProcedural safeguards include independent review of the authorization’s legal validity and of the remuneration decision. Review may be judicial or conducted by a distinct higher authority, as permitted by the agreement. Domestic administrative law, due process, and judicial review rules govern questions such as notice, evidence, reasons, and challenges to the decision. Reviewability does not necessarily require every challenge to suspend an authorization; that issue depends on the applicable legal system."
    },
    {
      "heading": "Medicines and national experience",
      "text": "Pharmaceutical patents have made compulsory licensing particularly significant for public health. Medicines can combine high research and development costs with comparatively low costs of reproducing an established product. Patent protection may enable the recovery of investment, while exclusive supply and pricing can restrict access. Compulsory licensing addresses the patent barrier in selected circumstances, but its effects depend on available manufacturers, procurement arrangements, regulatory approval, and health-system capacity.\n\nBrazil issued a compulsory license for efavirenz, an antiretroviral medicine used in HIV treatment, in 2007. The measure concerned public non-commercial use within the national treatment program. Supply initially relied on imported generic medicine, with domestic production following later. The case illustrates how a license can support both immediate procurement and a longer-term manufacturing strategy, without making domestic production a prerequisite for the initial authorization.\n\nThailand authorized government use of patents covering efavirenz in 2006 and additional medicines in 2007, including the antiretroviral combination lopinavir/ritonavir and the cardiovascular drug clopidogrel. These authorizations became prominent examples of patent flexibility being used for public treatment programs. Their legal form also demonstrated that government use is not confined to a single disease category or to medicines needed during a formally declared national emergency.\n\nIndia’s first compulsory patent license was granted in 2012 to Natco for sorafenib tosylate, marketed by Bayer as Nexavar. The Controller applied Section 84 of the Patents Act, which permits applications after three years from patent grant on specified grounds. The decision addressed reasonable public requirements, reasonably affordable price, and working of the invention in India. An initial royalty of 6 percent of net sales was subsequently increased to 7 percent on appeal.\n\nThe Indian case is notable for the specificity of its statutory reasoning. It was not a general authorization to copy patented medicines, nor did it establish that every expensive pharmaceutical product qualifies for a license. Later applicants have had to satisfy the statutory requirements on their own evidence, including requirements concerning efforts to obtain voluntary permission. Questions about domestic working likewise require attention to the governing law and case-specific circumstances rather than an assumption that importation is invariably insufficient.\n\nPatent authorization alone cannot ensure access. A generic medicine supplier still needs suitable ingredients, manufacturing capability, quality controls, and relevant approvals. Some medicines are difficult to reproduce because production depends on specialized biological systems or confidential process knowledge. In addition, a single product may be covered by separate patents on the active ingredient, formulation, manufacturing process, or delivery device. Identifying the necessary rights and coordinating supply can therefore matter as much as the licensing decision itself."
    },
    {
      "heading": "Exporting medicines under the TRIPS special system",
      "text": "The original TRIPS Article 31(f) generally required authorized use to be predominantly for the supply of the domestic market of the member granting the license. This created a structural difficulty for countries without sufficient pharmaceutical manufacturing capacity. A country might authorize use of a patent but lack a producer capable of making the medicine, while a potential exporting country faced restrictions on licensing production primarily for export.\n\nParagraph 6 of the Doha Declaration recognized the problem. A WTO decision of 30 August 2003 established a waiver-based solution, and a protocol adopted in 2005 provided for its incorporation into TRIPS. The resulting Article 31bis amendment entered into force on 23 January 2017. It allows qualifying production and export of pharmaceutical products under compulsory licenses through a special system with notification and anti-diversion requirements.\n\nAn eligible importing member must notify the WTO of the names and expected quantities of the needed products. Except for least-developed members, it must establish that it has insufficient or no manufacturing capacity for the products concerned. Where a relevant patent exists in its territory, it must confirm that it has granted or intends to grant an appropriate license. Least-developed members receive particular treatment, and some WTO members have declared that they will not use the system as importers or will use it only in emergencies.\n\nThe exporting member must issue a license limited to the quantities necessary to meet the notified needs, with the entirety of production under that license exported to the designated destinations. Products must be clearly identified through labeling or marking, with special packaging or product characteristics where feasible and without a significant price impact. Before shipment, the licensee must post specified information about quantities and distinguishing characteristics on a website. These measures are intended to reduce diversion into markets not covered by the arrangement.\n\nRemuneration is payable in the exporting member, taking account of the economic value of the authorization to the importing member. Where remuneration has been paid in the exporting member under the system, the importing member’s corresponding remuneration obligation is waived for the same products. The arrangement thereby addresses the possibility of duplicative payment when production and importation require licenses in different territories.\n\nThe best-known completed use involved Canada and Rwanda. Under Canada’s implementing legislation, Apotex manufactured a fixed-dose combination of zidovudine, lamivudine, and nevirapine for Rwanda, with shipments in 2008 and 2009. The episode demonstrated that the system could function, while also drawing attention to the coordination required among procurement, notifications, patents, manufacturing, and regulatory procedures. Its limited use does not by itself establish whether the mechanism is unnecessary or ineffective: voluntary licensing, unpatented supply, purchasing arrangements, and procedural burdens all affect the demand for it."
    },
    {
      "heading": "Copyright statutory licenses and cultural distribution",
      "text": "Copyright compulsory licensing often addresses repeated transactions rather than exceptional access to a single invention. A broadcaster, recording producer, or digital service may use very large repertoires involving many right holders. Individually negotiating every permission can be costly or impractical. A statutory license can replace individual consent for a defined category of use with standardized eligibility rules, reporting duties, and payment obligations.\n\nThe United States introduced a compulsory mechanical licensing arrangement for musical compositions in the Copyright Act of 1909. Its modern successor is found in Section 115 of the Copyright Act. Broadly, once the relevant conditions have been met concerning authorized distribution of phonorecords of a nondramatic musical work, qualifying users may obtain a license to make and distribute phonorecords subject to statutory requirements. The license concerns the musical composition, not permission to copy another producer’s sound recording.\n\nThis distinction between composition and recording is fundamental. A commercially released song commonly embodies separate copyrights in the underlying music and lyrics and in a particular recorded performance. A license covering one does not automatically clear the other. Section 115 also does not supply a general synchronization license for placing music in films or advertisements, nor does it create unrestricted authority to transform a work into a substantially different composition.\n\nThe Music Modernization Act of 2018 reorganized United States mechanical licensing for covered digital activities. Beginning in 2021, a blanket licensing system administered by the Mechanical Licensing Collective became available for qualifying digital music providers. Statutory duties include identifying works and owners, processing usage information, distributing royalties, and addressing unmatched royalties. The system combines a legislatively established license with centralized administration rather than requiring a separate individually negotiated license for every composition.\n\nUnited States law also provides a statutory license under Section 114 for certain noninteractive digital performances of sound recordings. Eligibility depends on conditions governing matters such as programming and the nature of the service. Interactive, on-demand services generally require negotiated sound-recording licenses instead. Other statutory arrangements, including certain cable and satellite retransmission licenses, reflect distinct legislative choices about distribution technologies and markets.\n\nInternationally, such systems remain constrained by the relevant rights and treaty provisions. The Berne Convention permits conditions on specified broadcasting rights and sound-recording rights while preserving remuneration and other safeguards. Its Appendix establishes carefully delimited translation and reproduction licensing procedures for eligible developing countries. These arrangements should also be distinguished from collective rights management, in which organizations administer rights on behalf of owners: collective administration may operate through voluntary mandates, statutory authority, or a combination, and does not inherently eliminate the need for consent."
    },
    {
      "heading": "Competition, technological dependence, and economic effects",
      "text": "Compulsory licensing can function as a remedy under competition law, but ownership of an exclusive right is not itself proof of unlawful market conduct. The relevant inquiry concerns the applicable competition rules, the market, and the specific behavior at issue. Refusal to license, discriminatory conditions, tying, or exclusionary agreements can raise different legal questions. A remedy may require access to protected technology where an authority finds the legal conditions for intervention satisfied.\n\nTRIPS Article 31(k) provides special treatment when unconsented use remedies a practice determined through judicial or administrative proceedings to be anticompetitive. In that situation, members need not apply the ordinary prior-negotiation requirement or the rule that production be predominantly for the domestic market. The need to correct the practice may also be considered when determining remuneration. This is a distinct legal route, not a general exemption for any applicant alleging that a patent restricts competition.\n\nIn the European Union, decisions concerning refusal to license intellectual property have emphasized exceptional circumstances. In Magill in 1995, the Court of Justice upheld a decision requiring access to television listing information in circumstances that included preventing the emergence of a new product for which there was potential consumer demand. In IMS Health in 2004, the Court further addressed conditions under which refusal to license could constitute abuse of a dominant position. These cases do not create a general duty to share every valuable protected asset with competitors.\n\nStandardized technologies create related issues. A standard-essential patent covers technology necessary to implement a technical standard. Owners may undertake to offer licenses on fair, reasonable, and non-discriminatory terms, commonly called FRAND terms. Litigation can concern royalty levels, negotiation conduct, and access to injunctions. A judicially determined FRAND license and a statutory compulsory license can both limit a proprietor’s practical ability to refuse access, but their legal bases differ. In Huawei v. ZTE in 2015, the Court of Justice addressed the conduct expected of patent owners and implementers in certain injunction disputes involving FRAND commitments.\n\nEconomic analysis distinguishes immediate access effects from longer-term effects on investment. Authorizing another producer can reduce prices, increase supply, or make follow-on innovation possible. The extent depends on entry costs, demand, manufacturing capacity, and the availability of alternative technologies. If production remains difficult or concentrated, removing the consent requirement may not generate substantial competition. Conversely, the credible possibility of a license can influence voluntary negotiations even when no authorization is ultimately issued.\n\nLonger-term effects depend on the predictability, frequency, scope, and remuneration of intervention. Narrow, transparent rules may produce different investment responses from broad or uncertain powers. Empirical evaluation is difficult because licenses are not randomly assigned: governments often act precisely where prices, supply conditions, or public needs are unusual. A price reduction after authorization may also reflect procurement changes, competition from alternative treatments, or negotiated discounts. Careful assessment therefore separates the legal decision, actual market entry, prices paid, quantities supplied, and changes in research or production investment."
    }
  ],
  "links": [
    "intellectual-property",
    "patent",
    "copyright",
    "intellectual-property-infringement",
    "intellectual-property-licensing",
    "public-domain",
    "fair-use",
    "trademark",
    "paris-convention",
    "trips-agreement",
    "world-trade-organization",
    "berne-convention",
    "united-states",
    "injunction",
    "administrative-law",
    "due-process",
    "judicial-review",
    "public-health",
    "competition-law",
    "european-union"
  ],
  "sources": [],
  "license": "https://creativecommons.org/licenses/by/4.0/"
}